CDK4 and breast carcinoma: From the FELINE clinical trial[14], using exome and single-cell RNA sequencing of serially collected biopsies from ER+ breast cancer patients treated with letrozole mono endocrine therapy or in combination with different doses of CDK4/6 inhibitor ribociclib, researchers tried to understand the early-stage breast cancer evolution and develop resistance.